Baird starts Catalyst Pharma with Outperform, $28 target
Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...
Baird raises Palantir stock price target to $100 on strong Q4 results
Palantir Technologies Inc . (NASDAQ:PLTR) saw its price target increased by Baird from $70.00 to $100.00, while the firm maintained a Neutral rating on the stock. The adjustment followed Palantir's ...
Fortinet downgraded to Neutral from Outperform at Baird
Baird downgraded Fortinet (FTNT) to Neutral from Outperform with a price target of $112, up from $105. The firm says “relatively full ...